ILMN:NSD-Illumina Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 111.06

Change

0.00 (0.00)%

Market Cap

USD 21.05B

Volume

5.43M

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-09 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 34.56B
NTRA Natera Inc

N/A

USD 23.36B
ICLR ICON PLC

N/A

USD 16.55B
MEDP Medpace Holdings Inc

N/A

USD 10.85B
EXAS EXACT Sciences Corporation

N/A

USD 9.58B
GH Guardant Health Inc

N/A

USD 5.49B
RDNT RadNet Inc

N/A

USD 4.43B
SHC Sotera Health Co

N/A

USD 3.91B
VCYT Veracyte Inc

N/A

USD 3.40B
TWST Twist Bioscience Corp

N/A

USD 3.12B

ETFs Containing ILMN

CURE:XETRA VanEck Genomics and Healt.. 5.36 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.98 % 0.00 %

N/A

USD 5.28M
XGES:LSE Xtrackers MSCI Genomic He.. 4.12 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 4.10 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.10 % 0.00 %

N/A

USD 9.83M
GNOG:LSE Global X Genomics & Biote.. 3.94 % 0.00 %

N/A

USD 9.83M
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.84 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 3.39 % 0.00 %

N/A

USD 2.77M
IBBQ Invesco Nasdaq Biotechnol.. 2.12 % 0.00 %

N/A

USD 0.04B
HEAL:SW iShares Healthcare Innova.. 1.84 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 1.83 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 1.83 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 1.73 % 0.00 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 1.65 % 0.00 %

N/A

CAD 0.01B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.73 % 0.00 %

N/A

USD 4.61B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.73 % 0.00 %

N/A

USD 5.12B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.73 % 0.24 %

N/A

USD 24.43B
IJH iShares Core S&P Mid-Cap .. 0.64 % 0.07 %

N/A

USD 98.63B
SPMD SPDR Russell Small Cap Co.. 0.64 % 0.06 %

N/A

USD 12.79B
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 3.86B
ALFA 0.00 % 0.65 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.40B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.06B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.67M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 6.25B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
IVOO Vanguard S&P Mid-Cap 400 .. 0.00 % 0.15 %

N/A

USD 2.51B
MIDU Direxion Daily Mid Cap Bu.. 0.00 % 1.10 %

N/A

USD 0.10B
MVV ProShares Ultra MidCap400 0.00 % 0.95 %

N/A

USD 0.15B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
UMDD ProShares UltraPro MidCap.. 0.00 % 0.95 %

N/A

USD 0.04B
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.23B
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

N/A

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

USD 1.99B
ZMID:CA BMO S&P US Mid Cap Index .. 0.00 % 0.00 %

N/A

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.00 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.00 % 0.00 %

N/A

N/A
BBIG:CA 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.89% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.89% 25% F 16% F
Trailing 12 Months  
Capital Gain -17.17% 51% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.17% 51% F 33% F
Trailing 5 Years  
Capital Gain -61.43% 38% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.43% 34% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -16.54% 34% F 15% F
Dividend Return -16.54% 34% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.52% 90% A- 56% F
Risk Adjusted Return -49.36% 26% F 13% F
Market Capitalization 21.05B 95% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector